Key Takeaways
- Flat year, cautious optimism ahead: FY26 revenue and bottom line were flat (±1%), but management believes the worst is behind them and expects a better year ahead, citing "cautious optimism."
- Raw material shock absorbed: Ammonia prices doubled from ₹50 to ₹100/kg in March, but the company passed costs through to customers and kept plants running via inventory and improved sourcing.
- Acetonitrile tailwind emerging: Antidumping duty benefits materialized late in the year; Chinese competitors pulled back and raised prices, improving Alkyl's market share in the final quarter.
- Kurkumbh project near the finish line: Mechanical completion expected end of June, with commissioning beginning next quarter; project economics unaffected by the delay or raw material price moves.
- What to watch next quarter: Whether the 5–10% volume growth expectation holds, how quickly the Kurkumbh plant ramps, and whether Chinese competitors sustain their less aggressive posture.
Raw Material Shock & Price Pass-Through
- Ammonia doubled in March: War-related sourcing disruptions pushed ammonia from ₹50 to ₹100/kg; the disruption was short (a week or two) as the company drew on inventory and improved sourcing to keep plants running.
- Pass-through worked: Finished good prices were raised to protect margins, and customers absorbed the increase because amines are a minor cost item (a "C item") in most customer bills of materials.
- Competitors face same squeeze: All players face the same raw material constraints, so management does not expect prices to return to pre-February levels quickly.
- Temporary margin bump in March: The company held raw material inventory at old, lower prices while finished good prices moved up, giving a one-time margin advantage that is not sustainable.
- Ammonia contracts now all short-term: Nobody is willing to commit to longer-term contracts at elevated prices, so all ammonia sourcing is on a short-term basis.
- Government support likely: Ammonia allocation (0.05% of national requirement) is expected to be supported by government because aliphatic amines go into agricultural inputs and drugs; the alternative would be importing finished material.
Kirat Patel: "At the beginning at every cycle, we gain because there is always that we quickly react to current raw material prices and change our finished good prices, while we do have contracts for the old or inventory of raw material with us. So there is a widening of margins in the initial stage. Then it settles down."
Competitive Dynamics by Product
- Acetonitrile turning favorable: Antidumping duty benefit materialized only toward the end of the year; Chinese competitors had cut prices in anticipation, but pipeline inventory cleared by December–January and market share improved in the last quarter as Chinese imports fell and their prices rose.
- ACN cost position: Management believes the company will be the lowest-cost manufacturer in acetonitrile for some time to come.
- Ethylamines stable: Only two players (Balaji and Alkyl) operate in this market; share is stable, prices stabilized and increased because alcohol feedstock costs rose, and margins are protected. Management believes Alkyl is probably the largest or second-largest ethylamines producer globally.
- Methylamines overcapacity deepened: A fourth player (Aarti) commissioned a plant into an already oversupplied market, creating even more overcapacity; management called the entry a "mystery" given existing capacity was sufficient. Absorption of all overcapacity will take "a lot of time."
- China anti-involution policy: Some benefit expected if Chinese competitors sustain reduced aggressiveness, but management tempered expectations: "not a dramatic benefit, maybe 5% more selling price," and Chinese players remain present in the market.
Kirat Patel: "It's a bit of a mystery why Aarti went into this industry when there was already overcapacity. There was enough capacity, and then they have put in a new plant. So we have had even more overcapacity."
Demand Environment
- Demand by segment: Pharma accounts for 50–60% of sales, agro for 15–20%, together making up 70–75% of the business.
- No demand slowdown yet: Management has not seen any demand impact from price hikes, though it is too early to tell; pharma demand is not expected to be affected, but some concern exists around agro due to El Niño and monsoon uncertainty.
- Pharma tailwinds: The sector is optimistic, and tariff exemptions have helped; peptide-related demand is still in early days since the product launched only in the last month, and the company is waiting to see actual growth materialize.
- Oil & gas tariff impact: One product supplying the oil and gas sector was impacted by tariffs.
- Volume growth expectation: Management expects 5–10% volume growth next year, consistent with the country growing at 5–7% and the company growing alongside it, though uncertainty remains high.
Kirat Patel: "It is a bit difficult to predict whether this will have an impact on the demand. At the moment, of course, we haven't seen it because it's too early."
Kurkumbh Project & Capacity
- Commissioning timeline: Mechanical completion expected at end of June, with commissioning beginning in the July–September quarter; the project was slightly delayed but economics are unaffected by the delay or by raw material and finished good price movements.
- Existing capacity sufficient: Enough capacity exists for current products for the next few years without additional investment; ethylamines capacity alone is sufficient for the next 4–5 years assuming 5–10% growth.
- Capex outlook: No major business project capex planned for FY27–28 beyond completing the Dahej new product plant and engineering projects, totaling around ₹80–90 crores; if R&D products succeed, a sudden capex requirement could emerge, otherwise only maintenance capex.
R&D Pipeline & New Products
- Near-term launches: Products already being launched are expected in the market by July.
- Pipeline status: Some products have reached the engineering stage, but the final investment decision has been deferred until market volatility settles; management needs a longer-term view given the 4–5 year cycle from conceptualization to commercialization.
- Survival rate: Over a dozen R&D projects are underway, but management estimates only 1 or 2 may survive to commercialization.
- Disclosure policy: Management declined to discuss specific R&D products, citing a policy of not talking about products until they are in the market.
Kirat Patel: "Out of these dozen, maybe 1 or 2 may survive to commercialization."
Margins & Cycle Dynamics
- Margin cycle mechanics: At the start of every cycle, margins widen because the company quickly reacts to current raw material prices and raises finished good prices while still holding old, lower-cost inventory; margins then settle down due to competition. When prices start declining, raw materials fall faster than finished goods, giving another temporary benefit.
- Bottom seen: Management is optimistic that margins going forward will be a little better than last year and believes the bottom has been reached, though whether improvement continues is a separate question.
- Price floor: Management does not think prices will come down to pre-February levels very soon; the damage to the petrochemical industry will take time to repair.
- Green ammonia watch: Management is monitoring green ammonia developments but nobody is yet offering it; expects breakthroughs in 3–5 years.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Kurkumbh commissioning | Mechanical completion end of June; commissioning begins | July–September quarter |
| Volume growth | 5–10% growth expected | FY27 |
| Supply chain stabilization | Ammonia and raw material supply chain to normalize | 3–6 months (management estimate) |
| New product launch | R&D products already being launched to enter market | July |
| New product investment decision | Final investment decision on engineering-stage R&D products | After market volatility settles (undated) |
| Green ammonia availability | Breakthroughs expected | 3–5 years |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | Flat, plus/minus 1% YoY |
| Volume growth | ~1% decline YoY; prices dropped 1%, combination ~2% drop |
| EBITDA margin outlook | Optimistic for improvement from FY26 levels; management believes worst is behind |
| Capacity utilization | 60% to 85% across most plants |
| Ammonia cost | Over ₹100/kg, up from ~₹50/kg pre-disruption |
| Acetonitrile selling price | ~₹200/kg currently, up from ~₹140–₹150/kg average last year |
| Methylamine selling price | ₹100–₹110/kg |
| Ethylamine selling price | ₹200+/kg |
| Volume growth guidance (FY27) | 5% to 10% expected, in line with country growth of 5%–7% |
| Planned capex (FY27–FY28) | ₹80 cr to ₹90 cr, primarily for completing existing projects and maintenance |
| Maintenance capex | ₹20 cr to ₹30 cr annually |
| Pharma share of sales | 50% to 60%; agro another 15%–20%, total ~70%–75% |
| R&D pipeline | Over a dozen projects at various stages; 1–2 may reach commercialization |
| Acetonitrile market size | ~30,000 tons; peptide opportunity ~10% of total |
| Balaji Amines new ACN capacity | 18,000 tons plant expected; management confident in cost leadership |